Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients

Inclusion Criteria: 1. Adults over 18 years old; 2. Time after transplantation greater than 3 months; 3. Time after treatment with anti-thymocyte globulin longer than 4 weeks; 4. Able and willing (in the investigator's opinion) to comply with all study requirements; 5. Provide written informed consent Exclusion Criteria: 1. Planned receipt of any vaccine (authorized or experimental), within 30 days before and after vaccination; 2. Prior receipt of an experimental or authorized vaccine with the possibility of impacting the interpretation of the study data (for example, vectorized vaccines by Adenovirus, any vaccines against coronavirus); 3. Administration of immunoglobulins and / or any blood products in the three months prior to the planned administration of the candidate vaccine; 4. Any history of angioedema or anaphylaxis; 5. Pregnancy, lactation or willingness / intention to become pregnant during the study; 6. Diagnosis or current treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ); 7. History of severe psychiatric illness that possibly affects your participation in the study; 8. Hemorrhagic disorder (eg, factor deficiency, coagulopathy or platelet disorder) or a previous history of significant bleeding or hematoma after IM injections or venipuncture; 9. Continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban); 10. Current suspected or known addiction to alcohol or drugs.